BRIDGEWATER, N.J., March 23 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, Inc., a leading provider of scientific information and analytics to the pharmaceutical and biotech fields, announced today that it has published the collective recommendations of an international team of healthcare experts on how payers can improve their risk-sharing approaches for expensive new therapies and technology.
“Health decision makers across the globe, such as Medicare in the U.S. and NICE in the U.K., are increasingly looking at ways of managing the uncertainty that often surrounds the therapeutic and economic value of new prescription drugs,” said Christopher Carswell, Editor, PharmacoEconomics. “Risk-sharing schemes are one way to allow reimbursement of expensive drugs and limit the cost burden on payers.”
This special issue of PharmacoEconomics is devoted entirely to the topic of “access with evidence development” and is intended to help “manage the tension between funding new but expensive treatments and obtaining value.”
The benchmark journal on the applications of pharmacoeconomics and quality-of-life assessment, PharmacoEconomics is an invaluable source of applied original research and educational material for the healthcare decision maker. The journal is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization.
Editor’s Note: For a free PDF look at PharmacoEconomics (2010, Vol. 28, No. 2) or to set an interview with Chris Carswell, please contact Tom Kivett at +1 212 727-2935 or email at tkivett@kivettandco.com
The company is a wholly owned subsidiary of Wolters Kluwer, U.S., part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Visit our website, YouTube or follow @Wolters_Kluwer on Twitter for more information about our customers, market positions, brands, and organization.
CONTACT: Tom Kivett, Kivett & Company Communications, +1-212-727-2935,
tkivett@kivettandco.com
Web site: http://www.wolterskluwerpharma.com/
